Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International's Accumulated Expenses history spans 5 years, with the latest figure at $42.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 29.87% year-over-year to $42.0 million; the TTM value through Dec 2025 reached $42.0 million, up 29.87%, while the annual FY2025 figure was $42.0 million, 29.87% up from the prior year.
  • Accumulated Expenses reached $42.0 million in Q4 2025 per KNSA's latest filing, up from $30.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $42.0 million in Q4 2025 to a low of $5.6 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $19.4 million, with a median of $12.7 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: soared 445.4% in 2022, then crashed 85.49% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $8.9 million in 2021, then surged by 237.73% to $30.1 million in 2022, then fell by 7.92% to $27.7 million in 2023, then rose by 16.69% to $32.4 million in 2024, then increased by 29.87% to $42.0 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Accumulated Expenses are $42.0 million (Q4 2025), $30.9 million (Q3 2025), and $36.0 million (Q2 2025).